Pharmaceuticals
Daewoong Infion obtained World's First Halal Certification for Biopharmaceutical Product Derived from Animal Cells
SEOUL, South Korea, Jan. 9, 2020 /PRNewswire/ -- Daewoong Infion Co. has
achieved world's first halal certification for animal cells-derived
biopharmaceuticals.
2020-01-09 09:51
3372
Publication of a Toxicological Study: A Milestone for Jennewein Biotechnologie for the GRAS Approval of the HMO-mix
RHEINBREITBACH, Germany, Jan. 9, 2020 /PRNewswire/ -- Jennewein Biotechnology announces another milestone in the worldwide approval of a new product generation, the "HMO-Mix." The data of the toxicological study, with the title "A Safety Evaluation of Mixed Human Milk Oligosaccharides in Rats," w...
2020-01-09 02:26
2556
Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
SHANGHAI and PHILADELPHIA, Jan. 8, 2020 /PRNewswire/ -- The Antengene board today announced the appointment of Mr.Mark J. Alles as an independent director of the company, effectiveJanuary 2, 2020. Mr. Alles is the former Chairman and Chief Executive Officer of Celgene Corporation, now a subsidiar...
2020-01-08 20:00
3186
Connect Biopharma Reports Positive Topline Data from Moderate-to-severe Atopic Dermatitis (AD) Phase 1b Study of CBP-201
Data show superior efficacy after four weeks of treatment and more rapid onset of action for CBP-201 compared with data from studies of current standard of care therapy for AD On Day 29, 42.9% and 50.0% of patients receiving CBP-201 300 mg or 150 mg, respectively, achieved "clear/almost clear" s...
2020-01-08 19:00
1053
CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma
SUZHOU, China, Jan. 8, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) announced that the first patient has been dosed in the Phase III GEMSTONE-304 study of the Company's anti-PD-L1 antibody CS1001 in combination therapy as first-line treatment in patients wit...
2020-01-08 13:45
3100
Daewoong Pharmaceutical Receives World's First Halal Certification for Biopharmaceutical Product Derived from Animal Cells through Indonesian Joint Venture, Daewoong Infion
SEOUL, South Korea, Jan. 8, 2020 /PRNewswire/ -- Daewoong Infion Co. has achieved world's first halal certification for animal cells-derived biopharmaceuticals. Daewoong Pharmaceutical Co., Ltd. (CEO Sengho Jeon) announced that Daewoong Infion, the company's joint venture with Infion, an In...
2020-01-08 11:00
1378
Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US
SUZHOU, China, Jan. 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, and Sirnaomics Inc. ("Si...
2020-01-08 08:00
9154
Rising Demand for IoT-enabled Pumps to Drive North American PD Pumps Market amid Economic Slowdown
Integration of machine learning, artificial intelligence in pumps to help improve efficiency and reduce maintenance costs, finds Frost & Sullivan SANTA CLARA, California, Jan. 8, 2020 /PRNewswire/ -- Driven by continued investments in the US oil and gas industry, along with increased activity in ...
2020-01-08 06:03
1171
Southstar Drug Gets Ready for the Future with Huawei Wi-Fi 6
MANILLA, Philippines, Jan. 7, 2020 /PRNewswire/ -- Recently, by choosing a wireless Wi-Fi-6 network from Huawei, Southstar Drug is able to operate its business more efficiently and at greater speed, with better access to resources,helping to boost employee productivity. Southstar Drug, a subsidi...
2020-01-08 00:01
1311
Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR™ Therapy for Relapsed or Refractory T-cell Malignancies
SUZHOU, China and SHANGHAI, Jan. 7, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell therapy company, today announced the initiation of an investigational study of GC027, the first product candidate developed usingTruUCAR™ to treat relapsed or refr...
2020-01-07 22:00
1052
genOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Their Partnership to All Animal Cell Models
genOway acquires additional rights to develop all animal cell models using the CRISPR/Cas9 system LYON, France, Jan. 7, 2020 /PRNewswire/ -- genOway, a public company and leader in developing genetically modified research models, today announced an important milestone in extending its strategic ...
2020-01-07 09:00
3007
InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab
SHANGHAI, Jan. 7, 2020 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd., a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, today announced that the company has entered into a clinical collaboration with a subsidiary of Merck & C...
2020-01-07 08:25
3393
Japanese Clinical Study of DiscGenics' Cell Therapy for Disc Degeneration Passes Initial Safety Review
SALT LAKE CITY and TOKYO, Jan. 7, 2020 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that IDCT has p...
2020-01-07 08:00
1439
Inovio Provides Update on Clinical Program Plans for 2020
Inovio to present 2020 program plans at Biotech Showcase 2020 Conference PLYMOUTH MEETING, Pennsylvania, Jan. 6, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that Inovio's President & CEO, Dr. J. Joseph Kim will present a corporate update of the company's clinical progr...
2020-01-06 21:00
2977
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Not intended for US-, Canada- and UK-based media - At the planned interim analysis, Phase III JAVELIN Bladder 100 study met the primary endpoint of prolonging overall survival (OS) as a first-line maintenance treatment versus standard of care - BAVENCIO is the first immunotherapy to signifi...
2020-01-06 20:00
4759
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
SHANGHAI and PHILADELPHIA, Jan. 6, 2020 /PRNewswire/ -- Antengene Corporation today announced its appointment of Mr.John Chin, MBA, as Chief Business Officer (CBO). He will be responsible for the company's global business development and commercialization, and will report directly to Dr.Jay Mei, ...
2020-01-06 20:00
3680
Abcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability
- Includes leading protein conjugation technologies and industry brands Lightning-Link® and CaptSure™ - Opportunity to combine Expedeon and Abcam's technologies to create new products to support research and diagnostic development CAMBRIDGE, England, Jan. 6, 2020 /PRNewswire/ -- Abcam plc, a glo...
2020-01-06 15:00
999
GPHL's international headquarters settle in Macao, first project during the fifth-term government of Macao SAR
GUANGZHOU, China, Jan. 6, 2020 /PRNewswire/ -- The beginning of 2020 witnessed key projects promoting the cooperation betweenGuangdong and Macao. On January 3 , Guangzhou Pharmaceutical Group (Macau) International Development Co., Ltd. (hereunder referred to as "the company") was established inMac...
2020-01-06 14:39
1339
Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment
GAITHERSBURG, Md. and AMBLER, Pa., Jan. 6, 2020 /PRNewswire/ -- Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, and Tavotek Biotherapeutics, a biotech c...
2020-01-06 09:00
3138
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
TAIZHOU, China, Jan. 3, 2020 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"),(NASDAQ: SXTC) announced today that on December 27, 2019 the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifyi...
2020-01-03 23:30
6797
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5310
